The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

The European Medicines Agency Review of Luspatercept for the Treatment of Adult Patients With Transfusion-dependent Anemia Caused by Low-risk Myelodysplastic Syndromes With Ring Sideroblasts or Beta-thalassemia

Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid through the European Union (EU) was issued for luspate...

Full description

Bibliographic Details
Main Authors:	Julio Delgado, Caroline Voltz, Milena Stain, Ewa Balkowiec-Iskra, Brigitte Mueller, Johanna Wernsperger, Iwona Malinowska, Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti
Format:	Article
Language:	English
Published:	Wiley 2021-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000616

Similar Items

Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept
by: Sigurd Delanghe, et al.
Published: (2022-12-01)

Luspatercept‐induced reduction in transfusion requirement in α‐thalassemia
by: Nicholas Jackson, et al.
Published: (2020-07-01)

LUSPATERCEPT IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES: REAL WORLD DATA
by: Y. Gong, et al.
Published: (2024-01-01)

Luspatercept for transfusion-dependent β-thalassemia: time to get real
by: Khaled M. Musallam, et al.
Published: (2023-08-01)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
by: Esther Natalie Oliva, et al.
Published: (2021-12-01)

The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
by: Julio Delgado, et al.
Published: (2021-07-01)

Highlights on the Luspatercept Treatment in Thalassemia
by: Yesim Aydinok
Published: (2023-02-01)

LUSPATERCEPT – A TREATMENT FOR THALASSEMIA?
by: Taimoor Hassan
Published: (2021-09-01)

LUSPATERCEPT – a better strategy for thalassemia?
by: Mustafa Saleem Patel, et al.
Published: (2021-12-01)

Luspatercept in patients with lower-risk myelodysplastic syndromes
by: Fenaux, P, et al.
Published: (2020)

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis
by: Eleftheria Hatzimichael, et al.
Published: (2022-10-01)

P1506: REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA
by: P. Delaporta, et al.
Published: (2022-06-01)

Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms
by: Francesca Vinchi, et al.
Published: (2024-03-01)

Myelodysplastic syndrome/myeloproliferative neoplasm with ringed sideroblasts and thrombocytosis
by: Azka Tasleem, et al.
Published: (2021-11-01)

Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome
by: Neha Chopra Narang, et al.
Published: (2016-11-01)

S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY
by: M. D. Cappellini, et al.
Published: (2022-06-01)

Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy
by: Musallam KM, et al.
Published: (2023-05-01)

IRON OVERLOAD IN NON-TRANSFUSED SIDEROBLASTIC ANEMIAS
by: Pippard, M, et al.
Published: (1982)

Treating Thalassemia Patients with Luspatercept: An Expert Opinion Based on Current Evidence
by: Filomena Longo, et al.
Published: (2023-03-01)

New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts
by: Lorena Bedotti Ribeiro, et al.

FIRST SINGLE-CENTER EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROME (LR-MDS) PATIENTS WITH TRANSFUSION DEPENDENCE REFRACTORY TO ERYTHROPOIETIN THERAPY
by: A. Jonasova, et al.
Published: (2024-01-01)

Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia
by: Antonio Piga, et al.
Published: (2022-12-01)

Comment: In Response to 'Megaloblastic Anemia with Ring Sideroblasts is not Always Myelodysplastic Syndrome'
by: Smeeta Gajendra
Published: (2017-03-01)

P1508: LUSPATERCEPT REDUCES THE BURDEN OF RED BLOOD CELL TRANSFUSION IN PATIENTS WITH BETA -THALASSEMIA AND COMORBIDITIES: THE EXPERIENCE OF A SINGLE THALASSEMIA AND SICKLE CELL UNIT IN A UNIVERSITY HOSPITAL
by: S. Delicou, et al.
Published: (2022-06-01)

Luspatercept in Low-Risk Myelodysplastic Syndrome: A Real-World Single Institution Case Series
by: Shamis Khan, et al.
Published: (2022-08-01)

When Ring Sideroblasts on Bone Marrow Smears Are Inconsistent with the Diagnosis of Myelodysplastic Neoplasms
by: Sandrine Girard, et al.
Published: (2022-07-01)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
by: Marion Divoux, et al.
Published: (2020-09-01)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
by: Ali T. Taher, et al.
Published: (2023-08-01)

Treatment patterns and outcomes with luspatercept in patients with lower‐risk myelodysplastic syndromes: A retrospective US cohort analysis
by: Sudipto Mukherjee, et al.
Published: (2024-01-01)

The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
by: Julio Delgado, et al.
Published: (2021-12-01)

Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
by: Mariane de Montalembert, et al.
Published: (2017-01-01)

P1518: LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA
by: V. Viprakasit, et al.
Published: (2022-06-01)

EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
by: G. Garcia-Manero, et al.
Published: (2024-01-01)

Cardiac and hepatic siderosis in myelodysplastic syndrome, thalassemia and diverse causes of transfusion-dependent anemia: the TIMES study
by: P. Joy Ho, et al.
Published: (2019-06-01)

5610224 THE USE OF LUSPATERCEPT IN PATIENTS WITH β -THALASSAEMIA AND MULTIPLE SYSTEMIC COMPLICATIONS INCREASES HEMOGLOBIN LEVEL, DECREASES TRANSFUSION BURDEN, AND IS UNAFFECTED BY COMPLICATIONS. SINGLE THALASSEMIA AND SICKLE CELL DEPARTEMENT’S EXPERIENCE.
by: K.M. Manganas, et al.
Published: (2023-04-01)

A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
by: Alejandro Lazo-Langner, et al.
Published: (2019-02-01)

Myelodysplastic syndrome/myeloproliferative neoplasm – ring sideroblast with myelofibrosis – A diagnostic dilemma/? A distinct entity
by: Amandeep Talwar, et al.
Published: (2021-01-01)

Sideroblastic anemia
by: P Bhandari, et al.
Published: (2016-03-01)

P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL
by: Thomas D. Coates, et al.
Published: (2023-08-01)

Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome
by: Tetsuro Ochi, et al.
Published: (2022-08-01)